For Health Care Professionals Outside the US


Discontinuation rates

FARYDAK discontinuation rates

Discontinuation due to adverse events, regardless of causality, was observed in 36.2% of patients.2


  1. Data on file. Clinical study report CLBH589D2308. Novartis Pharmaceuticals Corp; Feb 2014.
  2. FARYDAK® (panobinostat). EU Summary of Product Characteristics. Secura Bio Limited; November 2019.